AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31675174 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-mm peritumoral expansion model
Number of subjects: 184
Study 31675174 — intervention group
Group type: COMPARATOR
Intervention: Clinical-radiological model
Number of subjects: 184
Study 29641212 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy (24 sessions, twice weekly)
Number of subjects: 34
Study 29641212 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 34
Study 27543447 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiselimod 0.1 mg
Number of subjects: 415
Study 27543447 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiselimod 0.2 mg
Number of subjects: 415
Study 27543447 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiselimod 0.4 mg
Number of subjects: 415
Study 27543447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415
Study 24823326 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 30
Study 24823326 — intervention group
Group type: COMPARATOR
Intervention: Passive Distraction (watching a movie)
Number of subjects: 30
Study 24823326 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 30
Study 22631662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling
Number of subjects: 2065
Study 22631662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored postcard reminder after tailored telephone counseling
Number of subjects: 2065
Study 22631662 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone counseling after tailored postcard reminder
Number of subjects: 2065
Study 22631662 — intervention group
Group type: COMPARATOR
Intervention: Reference group (no intervention)
Number of subjects: 2065
Study 22631662 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention effect in ever-screened men
Number of subjects: 2065
Study 20503809 — intervention group
Group type: EXPERIMENTAL
Intervention: Certified Safe Farm (CSF) intervention
Number of subjects: 185
Study 18762864 — intervention group
Group type: EXPERIMENTAL
Intervention: Kefir (oral lavage and 250 ml swallowed)
Number of subjects: 40
Study 18762864 — intervention group
Group type: COMPARATOR
Intervention: 0.09% NaCl (oral lavage twice a day)
Number of subjects: 40
Study 15820913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 246
Study 15820913 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/day
Number of subjects: 246
Study 15820913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 15189747 — intervention group
Group type: EXPERIMENTAL
Intervention: H/M (75% LP/25% NPL)
Number of subjects: 89
Study 15189747 — intervention group
Group type: COMPARATOR
Intervention: LP + N (Insulin lispro + NPH)
Number of subjects: 89
Study 15189747 — intervention group
Group type: EXPERIMENTAL
Intervention: H/M
Number of subjects: 89
Study 15189747 — intervention group
Group type: COMPARATOR
Intervention: LP + N
Number of subjects: 89
Study 11095321 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg once daily
Number of subjects: 209
Study 11095321 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg once daily
Number of subjects: 209
Study 11095321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 9037573 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone (30 mg/day)
Number of subjects: 46
Study 9037573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 9037573 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine or ranitidine
Number of subjects: 46
Study 1608985 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlopentin (diacetyl-splenopentin)
Number of subjects: 0
Study 1608985 — intervention group
Group type: COMPARATOR
Intervention: Caffeine
Number of subjects: 0
Study 3981627 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week core curriculum plus additional sessions through Grades 7 and 8
Number of subjects: 22
Study 3981627 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 22
Study 3356051 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (20 mg.kg‐1 administered rectally)
Number of subjects: 40
Study 3356051 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (1 mg.kg‐1 administered intramuscularly)
Number of subjects: 40
Study 30779496 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressed lithium disilicate inlays from milled wax patterns (group CIDW)
Number of subjects: 30
Study 30779496 — intervention group
Group type: COMPARATOR
Intervention: Milled lithium disilicate inlays from conventional impression (group CICAD)
Number of subjects: 30
Study 28789647 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Number of subjects: 76
Study 28789647 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splint
Number of subjects: 76
Study 28789647 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo laser
Number of subjects: 76
Study 28789647 — intervention group
Group type: COMPARATOR
Intervention: Control (without bruxism)
Number of subjects: 76
Study 26318269 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient treatment
Number of subjects: 604
Study 26318269 — intervention group
Group type: COMPARATOR
Intervention: Day hospital treatment
Number of subjects: 604
Study 23994420 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 600 mg/day
Number of subjects: 66
Study 23994420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 22206271 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy and high-protein diet (group B, n = 12, 4.2 g/kg/d protein and 150 kcal/kg/d)
Number of subjects: 32
Study 22206271 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy and high-protein diet (group C, n = 12, 4.7 g/kg/d protein and 150 kcal/kg/d)
Number of subjects: 32
Study 22206271 — intervention group
Group type: COMPARATOR
Intervention: Standard preterm formula (group A, n = 8, 3.7 g/kg/d protein and 129 kcal/kg/d)
Number of subjects: 32
Study 19269020 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg b.i.d.
Number of subjects: 20
Study 19269020 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 250 mg b.i.d.
Number of subjects: 20
Study 19269020 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no treatment)
Number of subjects: 20
Study 16481945 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary rehabilitation (n = 59) for 70 hours
Number of subjects: 120
Study 16481945 — intervention group
Group type: COMPARATOR
Intervention: Individual physiotherapy (n = 61) for 10 hours
Number of subjects: 120
Study 12237738 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg lercanidipine
Number of subjects: 25
Study 12237738 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg lercanidipine
Number of subjects: 25
Study 12237738 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during run-in period)
Number of subjects: 25
Study 10436254 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glyburide plus metformin (5, 7.5 or 10 mg/day glyburide and 800, 1,200 or 1,600 mg/day metformin)
Number of subjects: 40
Study 10436254 — intervention group
Group type: COMPARATOR
Intervention: High-dose glyburide alone (5, 10 or 15 mg/day)
Number of subjects: 40
Study 10436254 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glyburide plus metformin
Number of subjects: 40
Study 10436254 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine clinical chemistry measurements, ECG, and ophthalmoscopic examinations
Number of subjects: 40
Study 8000659 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cefotetan preoperatively
Number of subjects: 136
Study 8000659 — intervention group
Group type: COMPARATOR
Intervention: 2 g cefoxitin preoperatively
Number of subjects: 136
Study 8000659 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g cefoxitin preoperatively followed by three postoperative doses
Number of subjects: 136
Study 2155791 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified RLND
Number of subjects: 235
Study 2155791 — intervention group
Group type: COMPARATOR
Intervention: Radical RLND
Number of subjects: 235
Study 513694 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing-impaired group
Number of subjects: 0
Study 513694 — intervention group
Group type: COMPARATOR
Intervention: Normal group
Number of subjects: 0
Study 513694 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure tone and speech ART
Number of subjects: 0
Study 31605180 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight or obese BMI (≥25 kg/m2)
Number of subjects: 801900
Study 31605180 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI ≥30 kg/m2)
Number of subjects: 801900
Study 31605180 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted BMI
Number of subjects: 801900
Study 30105357 — intervention group
Group type: EXPERIMENTAL
Intervention: 76% rhodopsin bleach at 5° eccentricity
Number of subjects: 26
Study 30105357 — intervention group
Group type: EXPERIMENTAL
Intervention: 76% rhodopsin bleach at 12° eccentricity
Number of subjects: 26
Study 30105357 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the ROC curve for 76% bleach at 5°
Number of subjects: 26
Study 30105357 — intervention group
Group type: EXPERIMENTAL
Intervention: Area under the ROC curve for 76% bleach at 12°
Number of subjects: 26
Study 27017895 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline-malate (CM) supplementation (12 g dextrose + 8 g CM)
Number of subjects: 17
Study 27017895 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) (12 g dextrose)
Number of subjects: 17
Study 23666589 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg IORA vancomycin
Number of subjects: 30
Study 23666589 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg IORA vancomycin
Number of subjects: 30
Study 23666589 — intervention group
Group type: COMPARATOR
Intervention: 1 g systemic vancomycin
Number of subjects: 30
Study 23563461 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% hyperbaric ropivacaine + 25 μg (0.5 ml) fentanyl
Number of subjects: 40
Study 23563461 — intervention group
Group type: COMPARATOR
Intervention: 5 mg (l ml) hyperbaric bupivacaine + 25 μg (0.5 ml) fentanyl
Number of subjects: 40
Study 20494434 — intervention group
Group type: EXPERIMENTAL
Intervention: PACT intervention
Number of subjects: 152
Study 20494434 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 152
Study 18179492 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities‐specific Balance Confidence Scale (ABC)
Number of subjects: 272
Study 18179492 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey of Activities and Fear of Falling in the Elderly (SAFE)
Number of subjects: 272
Study 18179492 — intervention group
Group type: COMPARATOR
Intervention: Activities‐specific Balance Confidence Scale (ABC) and Survey of Activities and Fear of Falling in the Elderly (SAFE)
Number of subjects: 272
Study 16639341 — intervention group
Group type: EXPERIMENTAL
Intervention: ESO 20 mg qd + FPV 1400 mg bid
Number of subjects: 0
Study 16639341 — intervention group
Group type: EXPERIMENTAL
Intervention: ESO 20 mg qd + FPV 700 mg bid + RTV 100 mg bid
Number of subjects: 0
Study 16639341 — intervention group
Group type: COMPARATOR
Intervention: FPV 1400 mg bid
Number of subjects: 0
Study 16639341 — intervention group
Group type: COMPARATOR
Intervention: FPV 700 mg bid + RTV 100 mg bid
Number of subjects: 0
Study 12762259 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment during the first hour
Number of subjects: 0
Study 12762259 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital thrombolysis
Number of subjects: 0
Study 12762259 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytics (third-generation agents like reteplase and tenecteplase)
Number of subjects: 0
Study 12845340 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 0
Study 8657946 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA (12.5, 25, and 50 mumol per kilogram body weight)
Number of subjects: 31
Study 8657946 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd‐EOB‐DTPA
Number of subjects: 31
Study 8657946 — intervention group
Group type: COMPARATOR
Intervention: Gd‐DTPA (0.1 mmol per kilogram body weight)
Number of subjects: 31
Study 1809524 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% Sn2 gel used while toothbrushing every day for three months
Number of subjects: 184
Study 1809524 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1% neutral NaF gel for three months followed by twice daily rinsing with a remineralizing mouthrinse
Number of subjects: 184
Study 1809524 — intervention group
Group type: COMPARATOR
Intervention: Non-compliant group
Number of subjects: 184
Study 7104246 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive relaxation
Number of subjects: 40
Study 7104246 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 40
Study 7104246 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback placebo
Number of subjects: 40
Study 31177739 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV+sIPV+bOPV
Number of subjects: 1917
Study 31177739 — intervention group
Group type: EXPERIMENTAL
Intervention: sIPV+wIPV+bOPV
Number of subjects: 1917
Study 31177739 — intervention group
Group type: EXPERIMENTAL
Intervention: wIPV+sIPV+bOPV
Number of subjects: 1917
Study 31177739 — intervention group
Group type: EXPERIMENTAL
Intervention: wIPV+wIPV+bOPV
Number of subjects: 1917
Study 28643477 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine polyphenols (RWPs) 600 mg/d
Number of subjects: 29
Study 26365326 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE alone (0.625 mg/d)
Number of subjects: 27739
Study 26365326 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + MPA (0.625 mg/d CEE and 2.5 mg/d MPA)
Number of subjects: 27739
Study 26365326 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CEE and CEE + MPA
Number of subjects: 27739
Study 26365326 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE alone
Number of subjects: 27739
Study 26365326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27739
Study 25002386 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended vertical transseptal approach (group A)
Number of subjects: 72
Study 25002386 — intervention group
Group type: COMPARATOR
Intervention: Transseptal approach (group B)
Number of subjects: 72
Study 22147942 — intervention group
Group type: EXPERIMENTAL
Intervention: irinotecan (CPT11), FU and LV (IFL)
Number of subjects: 506
Study 22147942 — intervention group
Group type: COMPARATOR
Intervention: 5‐fluorouracil and leucovorin (FU/LV)
Number of subjects: 506
Study 20565840 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cervical carcinoma (CC)
Number of subjects: 37
Study 20565840 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CIN
Number of subjects: 37
Study 20565840 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 37
Study 19124372 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized formoterol fumarate (20 microg) inhalation solution for nebulization (FFIS)
Number of subjects: 569
Study 19124372 — intervention group
Group type: COMPARATOR
Intervention: Formoterol fumarate dry powder inhalation (12 microg) (FA)
Number of subjects: 569
Study 15679563 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (n = 216)
Number of subjects: 427
Study 15679563 — intervention group
Group type: COMPARATOR
Intervention: Boric acid in alcohol (n = 211)
Number of subjects: 427
Study 12854787 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional tapered cast posts and cores (n = 14)
Number of subjects: 31
Study 12854787 — intervention group
Group type: EXPERIMENTAL
Intervention: ParaPost system prefabricated gold posts with cast cores (n = 13)
Number of subjects: 31
Study 12854787 — intervention group
Group type: EXPERIMENTAL
Intervention: ParaPost system cast posts and cores (n = 13)
Number of subjects: 31
Study 12854787 — intervention group
Group type: EXPERIMENTAL
Intervention: Radix‐Anchor posts (n = 10)
Number of subjects: 31
Study 10556133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (500 microg twice a day) for 4 weeks
Number of subjects: 13
Study 8633829 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with slow‐acting antirheumatic drugs (SAARDs)
Number of subjects: 238
Study 8633829 — intervention group
Group type: COMPARATOR
Intervention: Delayed introduction of treatment with slow‐acting antirheumatic drugs (SAARDs)
Number of subjects: 238
Study 1361594 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose inhaled beclomethasone dipropionate (BDP) 1500 micrograms/day
Number of subjects: 143
Study 1361594 — intervention group
Group type: COMPARATOR
Intervention: Low-dose inhaled beclomethasone dipropionate (BDP) 300 micrograms/day
Number of subjects: 143
Study 1361594 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high-dose and low-dose BDP
Number of subjects: 143
Study 6711997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 6
Study 6711997 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine plus low flow oxygen
Number of subjects: 6
Study 29982658 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated weight gain between birth and 5 years
Number of subjects: 2345
Study 29982658 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated weight gain in LBW children (BW < 2.5 kg)
Number of subjects: 2345
Study 29982658 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated weight gain in children with BW ≥ 2.5 kg
Number of subjects: 2345
Study 29982658 — intervention group
Group type: COMPARATOR
Intervention: Birthweight (BW)
Number of subjects: 2345
Study 30367680 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine follow-up by an anesthesia professional at postoperative days 1 and 3
Number of subjects: 5600
Study 30367680 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control phase)
Number of subjects: 5600
Study 26907728 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray
Number of subjects: 20
Study 26907728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 25135805 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacist intervention discussing patients' beliefs about their medicines
Number of subjects: 200
Study 25135805 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 200
Study 23137805 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg nasal nicotine
Number of subjects: 29
Study 23137805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 20717693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue condition (F) after high-level isometric contractions (HIC) at 60% of maximal voluntary contraction
Number of subjects: 14
Study 20717693 — intervention group
Group type: COMPARATOR
Intervention: No fatigue condition (NF) before high-level isometric contractions (HIC)
Number of subjects: 14
Study 19083165 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol instillation (PEI)
Number of subjects: 61
Study 19083165 — intervention group
Group type: COMPARATOR
Intervention: Long-acting octreotide alone (Control)
Number of subjects: 61
Study 16087974 — intervention group
Group type: EXPERIMENTAL
Intervention: High PA diet (40% of energy as fat, 16.8% as PA, and 16.4% as OA; n = 21)
Number of subjects: 43
Study 16087974 — intervention group
Group type: COMPARATOR
Intervention: High OA diet (40% of energy as fat, 1.7% as PA, and 31.4% as OA; n = 22)
Number of subjects: 43
Study 12584832 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Wenyang Huoxue Lishui (YWHL) treatment
Number of subjects: 49
Study 12584832 — intervention group
Group type: COMPARATOR
Intervention: Captopril (control)
Number of subjects: 49
Study 10355617 — intervention group
Group type: EXPERIMENTAL
Intervention: Superbrush
Number of subjects: 36
Study 10355617 — intervention group
Group type: COMPARATOR
Intervention: Elmex
Number of subjects: 36
Study 10355617 — intervention group
Group type: COMPARATOR
Intervention: Braun
Number of subjects: 36
Study 7939438 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP 20 micrograms intranasally or 200 micrograms orally
Number of subjects: 392
Study 7939438 — intervention group
Group type: EXPERIMENTAL
Intervention: Alarm treatment
Number of subjects: 392
Study 7939438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392
Study 3124648 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 41
Study 3124648 — intervention group
Group type: COMPARATOR
Intervention: Wedge biopsy
Number of subjects: 41
Study 28285574 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality exercise program using Kinect (IG1)
Number of subjects: 33
Study 28285574 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional exercise program using a paper booklet (IG2)
Number of subjects: 33
Study 28285574 — intervention group
Group type: COMPARATOR
Intervention: Usual care (CG)
Number of subjects: 33
Study 28002202 — intervention group
Group type: EXPERIMENTAL
Intervention: HFM + BH4 (5 mg/kg)
Number of subjects: 30
Study 28002202 — intervention group
Group type: COMPARATOR
Intervention: HFM alone
Number of subjects: 30
Study 24885178 — intervention group
Group type: EXPERIMENTAL
Intervention: exposure to nature
Number of subjects: 268
Study 24885178 — intervention group
Group type: EXPERIMENTAL
Intervention: relaxation
Number of subjects: 268
Study 24885178 — intervention group
Group type: COMPARATOR
Intervention: control group (lunch break spent as usual)
Number of subjects: 268
Study 22459264 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761® (240 mg once daily)
Number of subjects: 410
Study 22459264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study 19706018 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol combination (DT)
Number of subjects: 24
Study 19706018 — intervention group
Group type: COMPARATOR
Intervention: Timolol monotherapy
Number of subjects: 24
Study 18757651 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration inspired oxygen
Number of subjects: 143
Study 18757651 — intervention group
Group type: COMPARATOR
Intervention: Low-concentration inspired oxygen
Number of subjects: 143